Detailed Information

Cited 0 time in webofscience Cited 0 time in scopus
Metadata Downloads

A multicenter prospective observational study on the safety and efficacy of tacrolimus in patients with myasthenia gravis

Authors
Ahn, Suk-WonJoo, In SooKim, Byung-JoSung, Jung-JoonKang, Sa-YoonOh, JeeyoungMinn, Yang-KiSuh, Bum ChunOh, Sun-YoungHong, Yoon-HoNam, Tai-SeungSeok, Jung ImPark, Young-EunShin, Ha YoungBin Cho, EunShin, Je-YoungSeok, Hung YoulPark, Jin-SungMm, Ju-HongSeok, Jin-MyoungKim, Byoung-Joon
Issue Date
15-8월-2017
Publisher
ELSEVIER
Keywords
Myasthenia gravis; MG; Tacrolimus; MGCS; ADR
Citation
JOURNAL OF THE NEUROLOGICAL SCIENCES, v.379, pp.271 - 275
Indexed
SCIE
SCOPUS
Journal Title
JOURNAL OF THE NEUROLOGICAL SCIENCES
Volume
379
Start Page
271
End Page
275
URI
https://scholar.korea.ac.kr/handle/2021.sw.korea/82556
DOI
10.1016/j.jns.2017.05.060
ISSN
0022-510X
Abstract
Introduction: Several clinical studies using tacrolimus revealed reasonable therapeutic mechanisms and efficacy in patients with myasthenia gravis (MG). However, long-period studies in a large number of patients with MG are limited; therefore, the aim of this study was to investigate the therapeutic efficacies and safety of tacrolimus in patients with MG during a 12 -month follow-up period. Methods: Tacrolimus was administered to 150 patients with MG who were recruited based on the inclusion criteria. Fifteen medical centers in Korea participated in this study. The efficacy of tacrolimus was assessed using MG composite scales (MGCS) and the prednisolone-sparing effect. And the adverse drug reactions (ADRs) of tacrolimus were monitored in each patient from the beginning of tacrolimus treatment to the end of the follow-up period. Results: After starting tacrolimus, the 32 patients were affected by ADRs, and consequentially 134 patients of the enrolled patients were followed up for 12 months. They showed that the mean prednisolone dosage significantly decreased (6.1 +/- 7.6 mg/day), compared to that in the baseline (11.3 +/- 9.5 mg/day), and MGCS significantly improved after 12 months of tacrolimus treatment, compared to that at the baseline. Conclusions: Our study showed that tacrolimus would be an effective immunosuppressant as an initial therapeutic agent in patients with MG; in addition, it showed tolerable safety profiles during the 12-month follow-up evaluation. (C) 2017 Published by Elsevier B.V.
Files in This Item
There are no files associated with this item.
Appears in
Collections
College of Medicine > Department of Medical Science > 1. Journal Articles

qrcode

Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.

Related Researcher

Researcher Kim, Byung Jo photo

Kim, Byung Jo
의과대학 (의학과)
Read more

Altmetrics

Total Views & Downloads

BROWSE